Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hailey, J.
Right arrow Articles by Wang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hailey, J.
Right arrow Articles by Wang, Y.
Vol. 1, 1349-1353, December 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Neutralizing Anti-Insulin-like Growth Factor Receptor 1 Antibodies Inhibit Receptor Function and Induce Receptor Degradation in Tumor Cells

Judith Hailey, Eugene Maxwell, Kathy Koukouras, W. Robert Bishop, Jonathan A. Pachter and Yan Wang1

Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, New Jersey 07033

Insulin-like growth factor receptor 1 (IGFR1) plays a crucial role in oncogenic transformation [C. Sell et al., Mol. Cell. Biol., 14: 3604–3612, 1994]. Compared with the normal human mammary epithelial cell line MCF12A, MCF7 human mammary carcinoma cells overexpress IGFR1 on the cell surface. To measure the effects of IGFR1 inhibition on tumor cells, we tested two mouse neutralizing antibodies against human IGFR1 in cell-based assays. Both MAB391 and anti-IR3 antibodies inhibit IGFR1 autophosphorylation upon IGF-I ligand stimulation with IC50s of 0.58 and 0.80 nM, respectively. When cells were treated with neutralizing anti-IGFR1 antibodies for >=4 h, the total receptor level was dramatically decreased. IGF-I-stimulated activation of AKT was also inhibited by anti-IGFR1 antibodies. Furthermore, MAB391 and anti-IR3 inhibited the growth of MCF7 cells in soft agar. In addition to MCF7 cells, MAB391 also inhibited IGFR1 autophosphorylation and induced IGFR1 down-modulation in HT29 colorectal and Du145 prostate cancer cells. Therefore, neutralizing antibodies against IGFR1 represent a valid approach to inhibit growth of tumor cells.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
PNAS, June 17, 2008; 105(24): 8387 - 8392.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
Y. Kusada, T. Morizono, A. Matsumoto-Takasaki, K. Sakai, S. Sato, H. Asanuma, A. Takayanagi, and Y. Fujita-Yamaguchi
Construction and Characterization of Single-chain Antibodies Against Human Insulin-like Growth Factor-I Receptor from Hybridomas Producing 1H7 or 3B7 Monoclonal Antibody
J. Biochem., January 1, 2008; 143(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q.-s. Ji, M. J. Mulvihill, M. Rosenfeld-Franklin, A. Cooke, L. Feng, G. Mak, M. O'Connor, Y. Yao, C. Pirritt, E. Buck, et al.
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
Mol. Cancer Ther., August 1, 2007; 6(8): 2158 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari
Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation
Cancer Res., February 1, 2007; 67(3): 1155 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Feng, Z. Zhu, X. Xiao, V. Choudhry, J. C. Barrett, and D. S. Dimitrov
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function
Mol. Cancer Ther., January 1, 2006; 5(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Kaneda and A. P. Feinberg
Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk
Cancer Res., December 15, 2005; 65(24): 11236 - 11240.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Wang, J. Hailey, D. Williams, Y. Wang, P. Lipari, M. Malkowski, X. Wang, L. Xie, G. Li, D. Saha, et al.
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Mol. Cancer Ther., August 1, 2005; 4(8): 1214 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Xia, S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn, S. M. Henshall, R. L. Sutherland, J. K. Pinski, et al.
EphB4 Expression and Biological Significance in Prostate Cancer
Cancer Res., June 1, 2005; 65(11): 4623 - 4632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. D. Cohen, D. A. Baker, C. Soderstrom, G. Tkalcevic, A. M. Rossi, P. E. Miller, M. W. Tengowski, F. Wang, A. Gualberto, J. S. Beebe, et al.
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti-Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
Clin. Cancer Res., March 1, 2005; 11(5): 2063 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Sachdev, J. S. Hartell, A. V. Lee, X. Zhang, and D. Yee
A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells
J. Biol. Chem., February 6, 2004; 279(6): 5017 - 5024.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al.
A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo
Cancer Res., December 15, 2003; 63(24): 8912 - 8921.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Polgar, G. Kispal, M. Lachmann, G. Paar, E. Nagy, P. Csere, E. Miko, L. Szereday, P. Varga, and J. Szekeres-Bartho
Molecular Cloning and Immunologic Characterization of a Novel cDNA Coding for Progesterone-Induced Blocking Factor
J. Immunol., December 1, 2003; 171(11): 5956 - 5963.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Blum, A. Gazit, and A. Levitzki
Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics
J. Biol. Chem., October 17, 2003; 278(42): 40442 - 40454.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh
An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation
Cancer Res., August 15, 2003; 63(16): 5073 - 5083.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.